Hyperoxaluria - Pipeline Review, H2 2016

  • ID: 3981274
  • Report
  • 44 pages
  • Global Markets Direct
1 of 5
Hyperoxaluria - Pipeline Review, H2 2016

Summary

Hyperoxaluria - Pipeline Review, H2 2016, provides an overview of the Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape.

Hyperoxaluria is defined by the presence of excess amounts of oxalic acid (oxalate) in the urine. Symptoms include severe or sudden abdominal or flank pain, blood in the urine, fever and chills, loss of appetite, nausea and vomiting. Treatment includes a low-oxalate diet and vitamin B-6.

Report Highlights

Hyperoxaluria - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 1 and 1 respectively.

Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperoxaluria (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Hyperoxaluria (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperoxaluria (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperoxaluria (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Hyperoxaluria Overview

Therapeutics Development

Pipeline Products for Hyperoxaluria - Overview

Hyperoxaluria - Therapeutics under Development by Companies

Hyperoxaluria - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Hyperoxaluria - Products under Development by Companies

Hyperoxaluria - Companies Involved in Therapeutics Development

Allena Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc

OxThera AB

Hyperoxaluria - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ALLN-177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALLN-230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-GO1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCR-PHXC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oxabact - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hyperoxaluria - Dormant Projects

Hyperoxaluria - Discontinued Products

Hyperoxaluria - Product Development Milestones

Featured News & Press Releases

Oct 04, 2016: Allena Pharmaceuticals and Health Advances Present Analysis of Recurrent Kidney Stone Disease at the Academy of Managed Care Pharmacy Nexus Conference

Sep 07, 2016: Allena Pharmaceuticals Strengthens Leadership Team, Names Edward Wholihan as Chief Financial Officer and Robert Alexander, PhD, to Board of Directors

May 05, 2016: FDA Grants Orphan Drug Designation to Allena’s Investigational Therapy for the Treatment of Pediatric Hyperoxaluria

Feb 10, 2016: Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria

Nov 12, 2015: Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week

Nov 04, 2015: Allena Pharmaceuticals to Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015

Aug 04, 2015: Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria

Mar 18, 2015: Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the Treatment of Hyperoxaluria

Nov 17, 2014: Allena Pharmaceuticals Presents Phase 1 Data On ALLN-177 At American Society Of Nephrology Kidney Week 2014

Nov 10, 2014: Allena Pharmaceuticals To Present Data on Lead Program ALLN-177 at ASN Kidney Week 2014

May 15, 2014: OxThera Strengthens Patent Portfolio for Treatment of Hyperoxaluria

Apr 29, 2014: Allena Pharmaceuticals Announces Positive Phase 1 Data of ALLN-177 for the Treatment of Kidney Stones

Jan 08, 2014: OxThera Initiates Clinical Trial in Primary Hyperoxaluria

Jun 04, 2013: OxThera Strengthens Patent Portfolio For Orphan Disease

Jun 07, 2012: OxThera Resumes Clinical Development Of Oxabact For Treatment Of Hyperoxaluria

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hyperoxaluria, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Hyperoxaluria - Pipeline by Allena Pharmaceuticals Inc, H2 2016

Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016

Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016

Hyperoxaluria - Pipeline by OxThera AB, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Hyperoxaluria - Dormant Projects, H2 2016

Hyperoxaluria - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Hyperoxaluria, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allena Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Dicerna Pharmaceuticals Inc
  • OxThera AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll